This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's Setting the Tone for Hologic's (HOLX) Q1 Earnings?
by Zacks Equity Research
Strength in the Breast Health business, Panther system and international business is likely to boost Hologic's (HOLX) top line in Q1.
Can Solid Consumables Drive Illumina's (ILMN) Q4 Earnings?
by Zacks Equity Research
Illumina's (ILMN) management is optimistic about witnessing solid demand across the NovaSeq portfolio, which also includes the S2 and S1 flow cells.
Factors Expected to Influence Microsoft's (MSFT) Q2 Earnings
by Zacks Equity Research
Microsoft's (MSFT) Q2 results gains from enterprise strength, robust Office 365 & Azure adoption.
Henry Schein Animal Health Spin-Off Approaches, Costs Mount (revised)
by Zacks Equity Research
Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.
Can Diagnostic Revenues Fuel PerkinElmer's (PKI) Q4 Earnings?
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter 2018 results are likely to benefit from the Diagnostics Segment's solid performance.
Can Overall Growth Fuel Align Technology's (ALGN) Q4 Earnings?
by Zacks Equity Research
Align Technology (ALGN) is likely to gain from strength in Invisalign space as well as Scanner and Service business in fourth-quarter 2018.
ResMed Launches Nasal Mask Devise, Extends AirFit Portfolio
by Zacks Equity Research
ResMed's (RMD) AirFit N30i with a top-of-head connection keeps tubing out of the wearers' way, thus letting them conveniently move and sleep in any position.
Quest Diagnostics' Core Diagnostics Strong Amid Several Woes
by Zacks Equity Research
Quest Diagnostics' (DGX) steady efforts to intensify focus on core diagnostic information services business and an intelligent capital management give investors ample reasons to cheer for.
Neogen Gains on Strong Genomic Arm Amid Stiff Competition
by Zacks Equity Research
Neogen's (NEOG) genomic business shows steady growth on acquisitions in Australia and Brazil. Stiff rivalry a cause of concern.
Illumina (ILMN) Is Up 1.45% in One Week: What You Should Know
by Zacks Equity Research
Does Illumina (ILMN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here is Why Growth Investors Should Buy Illumina (ILMN) Now
by Zacks Equity Research
Illumina (ILMN) could produce exceptional returns because of its solid growth attributes.
Can Medical Devices Strength Drive Abbott (ABT) Q4 Earnings?
by Zacks Equity Research
Abbott (ABT) Q4 results likely to show continued growth in Medical Devices business.
Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
On the success of the Elevate 2020 program, along with augmenting reimbursements for tests, Myriad Genetics (MYGN) seems to be well-positioned to deliver strong financial results in fiscal 2019.
Henry Schein Animal Health Spin-Off Approaches, Cost Mounts
by Zacks Equity Research
Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.
Illumina (ILMN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed at $305.63 in the latest trading session, marking a +0.05% move from the prior day.
The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana
Why You Should Consider Buying Omnicell (OMCL) Stock Now
by Zacks Equity Research
Omnicell (OMCL) is pulling out all the stops to strengthen the medication adherence segment.
5 Great Medical Stocks to Buy Ahead of Q4 Earnings
by Swarup Gupta
A Reuters review of Wall Street Research firms reveals that health care is the most favored of the S&P 500's 11 major sectors.
QIAGEN QFT-Plus Ok'd in Canada, Test Customer Base Expands
by Zacks Equity Research
QIAGEN (QGEN) progresses with plans to widen customer base for QuantiFERON-TB Gold Plus test.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina's (ILMN) product launches continue to contribute to the top line. The company's recent broadening of genotyping sequencing line buoys optimism.
Has Illumina (ILMN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ILMN) Outperforming Other Medical Stocks This Year?
Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Illumina (ILMN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed the most recent trading day at $307.89, moving +1.72% from the previous trading session.
3 Medical Stocks Likely to Emulate Illumina's Success in 2019
by Urmimala Biswas
Illumina's (ILMN) gains are indeed staggering. But is it the sole star in the firmament setting benchmarks for others to try and emulate?
Here's Why You Should Buy Express Scripts (ESRX) Stock Now
by Zacks Equity Research
Strong demand for Express Scripts' (ESRX) solutions like SafeGuardRx, 90-day supply for chronic medications, exclusive Accredo Specialty Pharmacy and advanced opioid solutions buoy optimism.